HM Payson & Co
- SEC CIK
- 0000928052
- Latest filing
- Jul 17, 2026
SNY holding history
Sanofi in every 13F filed by HM Payson & Co, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SNY overviewAll 13F holders of SNYFull Q2 2026 holdings
- Shares (Q2 2026)
- 7,582
- Value
- $323.4K
- % of portfolio
- <0.1%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 7,582 | $323.4K | <0.1% | −566−6.9% | Reduced | Holders |
| Q1 2026 | 8,148 | $392.6K | <0.1% | +900+12.4% | Added | Holders |
| Q4 2025 | 7,248 | $351.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2025 | 7,248 | $342.1K | <0.1% | +235+3.4% | Added | Holders |
| Q2 2025 | 7,013 | $338.8K | <0.1% | +744+11.9% | Added | Holders |
| Q1 2025 | 6,269 | $347.7K | <0.1% | +674+12.0% | Added | Holders |
| Q4 2024 | 5,595 | $269.8K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 5,595 | $322.4K | <0.1% | −969−14.8% | Reduced | Holders |
| Q2 2024 | 6,564 | $318.5K | <0.1% | +644+10.9% | Added | Holders |
| Q1 2024 | 5,920 | $287.7K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 5,920 | $294.4K | <0.1% | −3,064−34.1% | Reduced | Holders |
| Q3 2023 | 8,984 | $481.9K | <0.1% | +682+8.2% | Added | Holders |
| Q2 2023 | 8,302 | $447.5K | <0.1% | −476−5.4% | Reduced | Holders |
| Q1 2023 | 8,778 | $477.7K | <0.1% | +46+0.5% | Added | Holders |
| Q4 2022 | 8,732 | $422.9K | <0.1% | +47+0.5% | Added | Holders |
| Q3 2022 | 8,685 | $330.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 8,685 | $435.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 8,685 | $446.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 8,685 | $435.0K | <0.1% | −1,151−11.7% | Reduced | Holders |
| Q3 2021 | 9,836 | $474.0K | <0.1% | −1,190−10.8% | Reduced | Holders |
| Q2 2021 | 11,026 | $581.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2021 | 11,026 | $545.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.